What intravenous methylprednisolone dose should be used for an adult with Stevens‑Johnson syndrome?

IV Steroid Dosing for Stevens-Johnson Syndrome

There is no established evidence-based dose of IV corticosteroids for Stevens-Johnson syndrome, and current UK guidelines explicitly state that high-quality supportive care should be prioritized over any specific systemic intervention, as no treatment has demonstrated conclusive benefit over conservative management. 1

Guideline Position on Steroids

The 2016 UK guidelines for SJS/TEN management found insufficient evidence to recommend for or against corticosteroids (or any systemic therapy including IVIg or cyclosporin). The guideline panel emphasized that:

• Major ascertainment bias, low patient numbers, and variation in timing/dosing made interpretation of steroid studies impossible
• High-quality multidisciplinary supportive care is the priority
• Any systemic interventions should ideally be used under specialist supervision in the context of clinical studies or registries 1

Dosing Regimens Reported in Literature

Despite lack of consensus, various methylprednisolone regimens have been used in clinical practice:

High-Dose Pulse Therapy

• 1000 mg IV daily for 3-4 days (initiated within 4 days of disease onset) showed promising results in a small prospective series, with dramatic improvement in skin eruptions and prevention of chronic ocular complications 2
• 500-1000 mg/day for 3 days was used in some Japanese case series 3

Moderate-Dose Regimens

• 1-1.5 mg/kg/day methylprednisolone was commonly used in retrospective studies, though efficacy was unclear 1
• 30 mg/kg IV over 30 minutes (the FDA-labeled high-dose regimen for life-threatening situations, repeatable every 4-6 hours for 48 hours) 4

Lower-Dose Regimens

• 40 mg/day was used in a recent case report with good outcomes 5
• Maximum doses up to 250 mg prednisolone equivalent for median 4 days were reported in European multicenter studies 1

Critical Safety Considerations

Cardiac arrhythmias and arrest have been reported with rapid IV methylprednisolone administration >0.5 grams over <10 minutes. Any dose ≥500 mg must be infused over at least 30 minutes 4.

Common Pitfalls:

• Sepsis risk: Corticosteroids may increase infection risk in these immunocompromised patients with extensive skin barrier loss. Two of four deaths in one TEN series involved sepsis in steroid-treated patients 3
• Timing matters: Earlier intervention (within 4 days of onset) appears more beneficial than delayed treatment 2, 6
• Duration uncertainty: Treatment courses ranged from 3 days to several weeks, with no clear optimal duration

Evidence Quality Assessment

A 2022 Cochrane review found very low-certainty evidence comparing corticosteroids versus no corticosteroids for disease-specific mortality (RR 2.55,95% CI 0.72-9.03), meaning we cannot determine if steroids help or harm 7. The comparison of etanercept versus corticosteroids showed low-certainty evidence that etanercept may reduce mortality (RR 0.51), suggesting corticosteroids may actually be inferior to TNF-alpha inhibitors 7.

Practical Approach When Steroids Are Used

If your institution uses corticosteroids for SJS (recognizing this lacks strong evidence):

1. Initiate early (within 4 days of symptom onset if possible)
2. Consider pulse dosing: 500-1000 mg IV methylprednisolone daily for 3 days, infused over ≥30 minutes
3. Monitor closely for sepsis, hyperglycemia, and cardiac complications
4. Taper gradually after clinical stabilization (typically 48-72 hours)
5. Ensure excellent supportive care regardless of systemic therapy choice

The most important clinical decision is ensuring transfer to a specialized center with multidisciplinary skin failure expertise, not which systemic therapy to choose 1.